Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" ...

Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock ...

Catalyst Pharmaceuticals (CPRX) announced that the company and its licensor SERB S.A. have entered into a Settlement Agreement with Teva ...

Catalyst Pharmaceuticals and its licensor SERB entered into a settlement agreement with Teva Pharmaceuticals resolving patent litigation brought by Catalyst and SERB in response to Teva's plans for a ...

Catalyst Pharmaceuticals' controversial $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...